Treatment Decision Making in Relapsed/Refractory Multiple Myeloma : Episode 4

Navigating MM Treatment: Sequencing Strategies and Integrating Talquetamab

June 19, 2024

By Donna Catamero, ANP-BC, OCN, CCRC
Beth Faiman, PhD, MSN, APN-BC, BMTCN, AOCN, FAAN, FAPO

News

Video

This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.

EP: 1.Case Study: 63-Year-Old Man With Multiple Myeloma

EP: 2.Empowering Patients With Myeloma Through Resources

EP: 3.Clinical Scenario: Treating Late-Line Relapsed Multiple Myeloma

EP: 4.Navigating MM Treatment: Sequencing Strategies and Integrating Talquetamab

EP: 5.Strategies for Discussing Potential Adverse Effects of Talquetamab in MM

EP: 6.Managing Toxicities From Talquetamab in Multiple Myeloma

EP: 7.Integrating GPRC5D-Targeting Bispecifics for Relapsed/Refractory MM

EP: 8.Clinical Advice on Caring for Patients Treated With Talquetamab

EP: 9.Insights on Evolving Treatment Strategies for Multiple Myeloma

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos

Image of a woman with wavy brown hair in front of a blue background

Photo of a woman with blond hair wearing a white and black blazer

Latest Conference Coverage

Safety Management With Amivantamab Plus Lazertinib in NSCLC

Tepotinib Shows Manageable Safety in MET Exon 14+ NSCLC

Adverse Events of Menin Inhibitors in AML: What Nurses Should Know

Ivonescimab/Chemo Ups PFS After Third-Generation TKI in EGFR+ NSCLC

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences

All rights reserved.